Ractigen Enters Strategic Partnership with University Medical Center Utrecht
This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
JIANGSU, China, June 05, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide...
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer